Date set for 1st Celebrex trial

Share this article:
The first product-liability trial for Pfizer’s COX-2 inhibitor Celebrex has been set for June 6 in Alabama state court, The Wall Street Journal reports. The plaintiff, Rosie Ware, alleges that Celebrex caused her 2005 stroke. The drug is the only one in its class still on the market, a fact that could pose a serious hurdle for her attorneys, the Journal notes. Suits for Bextra, which was withdrawn last April, could be harder to defend. More than 200 federal cases for the two drugs have been consolidated before Judge Charles Breyer of US District Court for the Northern District of California. Pfizer put a “black-box” warning on Celebrex in August, following an FDA recommendation, stating that the drug may increase the risk of cardiovascular events, including heart attack and stroke. Safety concerns have hurt sales, which fell 48% last year to $1.73 billion.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies